RLAY - Relay Therapeutics, Inc. News

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Bu

defenseworld.net

Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE

Bank of America Corp DE raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 86.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing

JP Morgan Maintains Overweight on Relay Therapeutics, Raises Price Target to $31

JP Morgan analyst Priyanka Grover maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight an

Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperfo

Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $30

Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and ra

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share in line with the Z

Relay Therapeutics Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $350.000K Miss $872.727K Estimate

Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the ana

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

Selected z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on Aug

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clini

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely ea

prnewswire.com

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pi

/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to

Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31

Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and r

Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target o

Canaccord Genuity analyst John Newman initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with

JP Morgan Initiates Coverage On Relay Therapeutics with Overweight Rating, Announces Price Target of

JP Morgan analyst Priyanka Grover initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a O

fool.com

Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year

Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weight

seekingalpha.com

Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinic

Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $26

Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises t

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $28

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Bu

fool.com

Is Relay Therapeutics a Buy After Promising Trial Results?

Relay had its initial public offering in 2020. The company's lead therapy is being tested for the tr

Advance Auto Parts Posts Upbeat Q1 Earnings, Joins IBM, Ralph Lauren And Other Big Stocks Moving Hig

U.S. stocks were lower on Thursday, with Nasdaq falling over 200 points. Advance Auto Parts Inc (NYS

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clini

fool.com

Why Relay Therapeutics Stock Popped on Wednesday

This was aided by a pair of bullish analyst updates. The two pundits raised their price targets and

Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $27

Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and ra

Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $21

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperfo

Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Ses

US stock futures higher, Lowe's shares fall after reporting earnings. Other stocks declining in

seekingalpha.com

Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise

Relay Therapeutics is undervalued as the market overlooks its potential to build a multi-indication

seekingalpha.com

Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalie

Relay Therapeutics Launches $175M Public Stock Offering

Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company

Relay Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinic

Raymond James Maintains Strong Buy on Relay Therapeutics, Raises Price Target to $26

Raymond James analyst Dane Leone maintains Relay Therapeutics (NASDAQ:RLAY) with a Strong Buy and

Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with

Relya Therapeutics Announces Initial Clinical Data From The Phase 2 ReInspire Trial Of Zovegalisib I

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowes

reuters.com

Relay's treatment shown to shrink vascular malformations in mid-stage trial

Relay Therapeutics said on Tuesday a mid-stage trial showed its experimental treatment can shrink va

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowes

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates

Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share versus the Zacks C

Relay Therapeutics Q1 EPS $(0.41) Misses $(0.37) Estimate, Sales $3.000M Beat $2.560M Estimate

Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.41) per share which missed the ana

Earnings Scheduled For May 5, 2026

Starbucks To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts change outlook & ratings for QGEN, AWI, CR, ATEN, PLUG, SBUX, CECO, CNC. Price targets

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $25

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Bu

Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $22

Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and r

Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $19

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperfo

Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $21

Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweig

Oppenheimer Maintains Outperform on Relay Therapeutics, Raises Price Target to $18

Oppenheimer analyst Matthew Biegler maintains Relay Therapeutics (NASDAQ:RLAY) with a Outperform

Relay Therapeutics Plans To Move Zovegalisib + Atirmociclib, Pfizer's Investigational, CDK4 Inhibito

Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling effi

Jones Trading Initiates Coverage On Relay Therapeutics with Hold Rating, Announces Price Target of $

Jones Trading analyst Boris Peaker initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a

Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $21

Barclays analyst Etzer Darout maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and ra

Relay Therapeutics To Present Initial Clinical Results, Preclinical Data For Zovegalisib In Vascular

Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company